建立面向公众的生物技术药物安全信息门户。
Sixth, establish a public-oriented biotechnology drug safety information portal.
医务人员缺乏生物技术药物知识及自律意识；
The medical personnel are lack of Biotechnology Medicines knowledge and self-discipline consciousness;
总结我国现行生物技术药物安全保障措施面临的主要问题；
Then I summarize the main problems that our current Biotechnology Medicines safety strategies face.
现在则投向更个体化的药物，即更有效治疗小部分病患的生物技术药物。
Now they are investing in more personalised medicine: biotech drugs that treat small groups of patients more effectively.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic versions of biotech drugs to come to market.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic ersions of biotech drugs to come to market.
但他也表示，这次他非常谨慎地看待新仿制药物的前景，因为生物技术药物很难仿制。
But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy.
生物技术药物研发的成功率稍高于小分子药物，但它们距离稳赚不赔的目标仍相距甚远。
Biologics have a somewhat better success rate than small molecule drugs, but they remain far from a sure bet.
既然市场上有很多靶向生物技术药物，那么研究者正开始试验两个靶向药物是否会比一个更好些。
Now that there are several targeted biotech drugs on the market, researchers are starting to test whether two targeted drugs are better than one.
所以真正的问题是那些希望成为非专利生物技术药物生产者的公司需要做出努力来赢得当局者的允许。
So the real question is what would-be manufacturers of biogenerics will be required to do to win approval here.
这严重影响了公众对生物技术药物的信心，从而在一定程度上影响了生物技术药物在我国的广泛使用。
It has seriously affected our public confidence in Biotechnology Medicines, thereby has affected the widespread use of Biotechnology Medicines in China.
目前，生物技术药物已经被越来越广泛地用于传统药物难以发挥作用的领域，与人类健康的关系日益密切。
Now, Biotechnology Medicines have been widely used in the areas where traditional medicine is difficult to play a role. The relationship between Biotechnology Medicines and human health is closer.
今年，礼来公司进入临床试验的药物一半是生物技术药物。公司计划自2011年起，每年有一个生物技术药物上市。
The company said half of its new drugs entering trials this year will be biologics and it plans to bring a new biotech product to market every year starting in 2011.
Vical公司致力于基于其DNA传递专利技术的生物技术药物的研发，目的是为了预防和治疗严重的威胁生命的疾病。
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
生物技术企业声称生物技术药物的复杂性和不可预知性意味着非专利生物技术药物在获得许可之前应经过广泛的人体测试实验。
The biotech industry says the complexity and unpredictability of biologically derived drugs mean generics should be subject to extensive tests in humans before being approved.
自20世纪70年代以来，分子生物学家已在物种之间转移基因，一次转移一种基因；他们的工作给我们带来了转基因农作物和生物技术药物。
Molecular biologists have been transferring genes between species, one at a time, since the 1970s; their work has given us genetically modified crops and biotechnology drugs.
但是直到目前他们还不能仿制复杂且昂贵的生物技术药物，这些药物越来越多的应用于治疗癌症、糖尿病和其它多发于像美国那样的富裕国家的疾病。
But they had never been able to copy the complex and expensive biotech medicines increasingly used to treat cancer, diabetes and other diseases in rich nations like the United States - until now.
发言中他还指出，因为药品商品化在美国以外的某些国家十分容易，所以美国一些药物上市通常晚于那部分国家，这也是美国生物技术公司为什么看起来发展缓慢的原因之一。
Burrill added that it's much easier to commercialize drugs outside the United States, so his home country will be getting new medical technology far later than other parts of the world.
阿米瑞斯生物技术公司开始运行时大规模使用也被称作合成生物技术的基因工程来培养能够制作治疗疟疾的药物的细菌。
Amyris started off using large-scale genetic engineering, also known as synthetic biology, to create bugs that make a malaria drug.
辉瑞公司上周宣布，已与罗氏和Alnylam一道，就这种形式的RNAi药物运输工具与加拿大生物技术Tekmira制药公司达成一笔交易。
Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp for this type of delivery vehicle for its RNAi drugs, joining Roche and Alnylam.
该守则将以科学为基础，并将考虑到生物技术的环境、社会经济和道德影响。 如同在药物方面的应用情况一样，对这些道德问题需要负责任地加以考虑。
The Code will be based on scientific considerations and will take into account the environmental, socio-economic and ethical implications of biotechnology.
就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
里纳特神经科学生物技术公司（Rinat Neuroscience）曾研制过一种实验性药物，可以急剧地降低啮齿类动物的食欲。
Rinat Neuroscience had an experimental drug that sharply reduced appetite in rodents.
它被广泛应用于生物技术、药物动力学、物理、经济、种群动力学、流行病学等领域。
It is widely applied in various domains such as biological technology, medicine dynamics, physics, economy, population dynamics and epidemiology.
中国已经成为药物、生物技术和医药设备世界上最热门的地方。
China has become international hottest destination for pharmaceuticals, biotech and medical devices.
结合其他生物技术，为疾病的发病机制研究、疾病诊断、药物开发等提供了全新的方法。
Combined with other biological technologies, it provides a new method for the investigation of the pathogenesis, diagnosis of diseases, and development of drugs.
发酵越来越多的类型正在使用，而且大多数新药物是生物技术产品。
More and more types of fermentation are being used, and most new medicines are products of biotechnology.
它被广泛应用于药物动力学、生物技术、经济、物理、流行病学、种群动力学等领域。
It is widely applied in various domains such as medicine dynamics, biological technology, economy, physics, population dynamics and epidemiology and so on.
随着生物技术、纳米技术和物理化学等多学科的飞速发展，磁性药物戡体的研究成为国内外导向药物领域的热门课题。
With rapid development of biotechnology, nano-technology and physical chemistry, research onthe magnetic drug carries becomes domestic and foreign important subject of magnetic drug delivery system.
随着生物技术、纳米技术和物理化学等多学科的飞速发展，磁性药物戡体的研究成为国内外导向药物领域的热门课题。
With rapid development of biotechnology, nano-technology and physical chemistry, research onthe magnetic drug carries becomes domestic and foreign important subject of magnetic drug delivery system.
应用推荐